Download Slide 1

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Atypical antipsychotic wikipedia , lookup

Drug discovery wikipedia , lookup

Stimulant wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Neuropharmacology wikipedia , lookup

NK1 receptor antagonist wikipedia , lookup

Nicotinic agonist wikipedia , lookup

Theralizumab wikipedia , lookup

Cannabinoid receptor antagonist wikipedia , lookup

Urban legends about drugs wikipedia , lookup

Bilastine wikipedia , lookup

Medical cannabis wikipedia , lookup

Psychopharmacology wikipedia , lookup

Transcript
SYNTHETIC CANNABINOIDS
Shelley A. Holmer MD
Duke University School of Medicine
©AMSP 2013
© AMSP 2013
1
CASE
• 27 yo woman who presented with
o Trembling
o Confusion
o Voices
o Fears people want to harm her
• No family history of psychosis
• Medical work-up → no major medical dx
• Recent use of the synthetic cannabinoids
© AMSP 2013
2
THIS LECTURE WILL REVIEW
• Background on cannabinoids
• Development of synthetic cannabinoids (SC)
• Risks associated with use
• Synthetic cannabinoids versus marijuana
© AMSP 2013
3
NATURAL CANNABINOIDS = MARIJUANA
•
• Comes from the plant Cannabis sativa
• Composed of > 500 compounds
• 66 compounds are "cannabinoids”
© AMSP 2013
4
CANNABINOIDS
Psychoactive
• Tetrahydrocannabinols (THC)
• Cannabinol (CBN)
• Cannabinodiol (CBDL)
Non-psychoactive
• Cannabigerols (CBG)
• Cannabichromenes (CBC)
• Cannabidiols (CBD)
© AMSP 2013
5
CANNABINOID RECEPTORS
CB1 receptor
• Psychoactive effects
• In brain and spinal cord (CNS)
• THC = partial agonist (positive effect)
• CBD = blocker of CB1
CB2 receptors
• Immune cells outside CNS
• Immune function and inflammation
© AMSP 2013
6
CANNABINOIDS:
PSYCHOACTIVE EFFECTS
•
•
•
•
•
•
•
Euphoria
Sensation of slowed time
Impaired judgment
Impaired coordination
Social withdrawal
Anxiety
Psychosis
© AMSP 2013
7
PSYCHOSIS
• Hallucinations +/• Delusions
• Without insight
• Alert/oriented
• Potential cannabinoid impact:
o THC may ↑ psychosis
o CBD may ↓ psychosis
© AMSP 2013
8
NON-PSYCHOACTIVE EFFECTS
• ↓ Nausea
• ↑ Appetite
• ↓ Pain
© AMSP 2013
9
CHRONIC USE LEADS TO
• Tolerance
o Increased amount required for same effect
o Diminished effect with use of same amount
• Withdrawal symptoms when stopped
o Irritability
o Anxiety
o ↓ Appetite
o Sleep problems
No legal detox
• Peak ~3-4 days, resolves after ~7 days
© AMSP 2013
10
THIS LECTURE WILL REVIEW
• Background on cannabinoids
• Development of synthetic cannabinoids (SC)
• Risks associated with use
• SC versus marijuana
© AMSP 2013
11
SYNTHETIC CANNABINOIDS (SC)
• Research compounds
• None approved for humans
• Most >potency than THC
JWH18
• Full agonists at the CB1 receptor
© AMSP 2013
12
SPICE: SC COMMERCIAL PRODUCTS
•
•
•
•
•
•
•
Spice
K2
Red magic
Red dragon
Diesel
Serenity
Blueberry Meditation
© AMSP 2013
13
SPICE
• SC sprayed on substance
• No dose control
• No regulation of ingredients
• Similar psychoactive effects to THC
• Marketed as herbal incense
“not for human use”
© AMSP 2013
14
SPICE USE
• First seen in Europe 2004
• First marketed in U.S. 2008
• 2012  used by 11 % of 12th graders
© AMSP 2013
15
SPICE: MEDICAL RECOGNITION
• Calls to US poison control centers
o2010: 3000
o2011: 7000
o2012: 5000
• 11,406 ER visits in 2010
© AMSP 2013
16
LEGAL STATUS OF SPICE
• 2008 Europe banned for health concerns
• 2011 US federal law deemed “no medical use”
• Possession illegal in 41 states
• Remains available
o Head shops
o Convenience stores/gas stations
o Internet
© AMSP 2013
17
WHY IS IT POPULAR?
• New/novel way to get “high”
• False belief SC safe because
o “Herbal”
o Legal
• Cannabis substitute
• Might ↓ cannabis withdrawal
• Inexpensive
• Accessible
© AMSP 2013
18
NOT DETECTED ON DRUG SCREENS
• Athletes
• Military personnel
• Students
• People on probation
• Employees with required drug screens
• Patients in drug tx programs
© AMSP 2013
19
THIS LECTURE WILL REVIEW
• Background on cannabinoids
• Development of synthetic cannabinoids (SC)
• Risks associated with use
• SC versus marijuana
© AMSP 2013
20
CASE
Clinical Course
• Pt immobile and incommunicative
• Hospitalized 2 mo with psychosis
• One year later psychosis free
© AMSP 2013
21
CASE REPORTS: ACUTE TOXICITY
Psychiatric
• Agitation
• Anxiety
• Paranoia
• Delusions
William S. Burroughs, 1914-1997, “Self Portrait,”
CU Libraries Exhibitions
• Hallucinations
© AMSP 2013
22
ACUTE TOXICITY
Neurologic
• Seizures
• Dilated pupils
• Jerking movements
• Decreased reflexes
© AMSP 2013
23
ACUTE TOXICITY
Cardiovascular
• ↑ Heart rate
• ↑ Blood pressure
• Chest pain
© AMSP 2013
24
ACUTE TOXICITY
Gastrointestinal
• Nausea
• Vomiting
• Diarrhea
© AMSP 2013
25
TREATMENT OF ACUTE INTOXICATION
Psychiatric: anxiety and psychosis
• Verbal reassurance “talk down”
• Medication for agitation (lorazepam)
• Seclusion/restraint only if serious danger
• Evaluate need for ongoing psychiatric care
© AMSP 2013
26
TREATMENT OF ACUTE INTOXICATION
Neurologic
• Seizure monitoring
• Evaluate muscle injury
o Muscle pain/weakness
o Labs: ↓ kidney function
© AMSP 2013
27
TREATMENT OF ACUTE INTOXICATION
Cardiac
• Monitor
o Blood pressure
o Heart rate
• Check EKG
• Labs: heart damage enzymes
o Troponin > 0.2 ng/ml
o CKMB > 3 ng/ml
© AMSP 2013
28
TREATMENT OF ACUTE INTOXICATION
Gastrointestinal
• Medication for nausea
• IV fluids
• Labs: check for low potassium
© AMSP 2013
29
LASTING CONSEQUENCES
Heart attacks
• 3 healthy adolescents with MI
• No personal or family history
• All smoked the SC “K2”
© AMSP 2013
30
LASTING CONSEQUENCES
May trigger psychosis if prior history
• 15 forensic inpts with psychotic illness
• All actively taking antipsychotics
• 5 with relapse of psychotic symptoms
• 24 hours after smoking JWH-018
© AMSP 2013
31
LASTING CONSEQUENCES
May cause first episode psychosis
• 10 men admitted for psychosis
• 9 had no FH of psychosis
• 7 needed meds
• 3 still psychotic 5 mo later
© AMSP 2013
32
LASTING CONSEQUENCES
Self harm/suicide while intoxicated
• Suicidal thoughts
• Reports of self-injury
© AMSP 2013
33
THIS LECTURE WILL REVIEW
• Background on cannabinoids
• Development of synthetic cannabinoids (SC)
• Risks associated with use
• SC versus marijuana
© AMSP 2013
34
Marijuana vs Synthetic Cannabinoids
•
•
•
•
Nature controls dose
Low-medium potency
Partial CB1 agonist
Contains CBD
•
•
•
•
© AMSP 2013
No dose control
High potency
Full CB1 agonist
No CBD
35
COMPARING SC TO MARIJUANA (MJ)
• MJ contains CBD: potential antipsychotic
• Natural marijuana may ↓ seizures
• No long-term SC studies
© AMSP 2013
36
CLINICAL CONCLUSIONS
• Data on optimal Rx not available
• Need ask patients about SC use
• Educate patients about SC risks
© AMSP 2013
37
OVERALL CONCLUSIONS
• Not a safe marijuana alternative
• Easy to obtain despite ban
• Inquire about use
• Risks not commonly known by public
• Not detected on urine tests
© AMSP 2013
38